Dear Kalle, Nice to see someone trying to inject some life back into this moribund board. Ah in the halcion days it was full of interesting discussion. That there is good and exciting science and pending products that could be represent disruptive technology is not in question. The real issues are whether this company will survive to reap the benefits or will it go under or be acquired. They have burned through fabulous amounts of money with no significant bottom line returns yet. Many of us old timers are way under water with retirement further away than ever due to unfulfilled promises. (Like phase II DIC data anticipated years ago and ongoing disputes with former partners.) Nonetheless, Atryn may come on line for heparin resistance soon and the markets for products like factor VIIa extraordinary. Many questions remain like why don't we have a big generic pharma partner (like TEVA or Dr Ready) by now, why don't the insiders buy, what in the world happened with LEO? How come we can't raise decent money if the pipeline is as promising as we are told? Don't say its "market conditions,"-- if the products are that good the partners and funding are there. Where is Genzyme or other established biotechs, the parents that have disowned us and so now we are orphaned, like the drugs we produce? Don't tell me its to save their vats of bacteria and CHO cells when this technology is so much more efficient. I could go on ad nauseam. We have all tried to get answers to these questions such as the excellent ones you pose and are met with evasiveness and obfuscation that has bred distrust and discouragement. May I suggest if you really wish for questions of this ilk to be asked in a way that might yield some meaningful info an appeal to Dew be made to pose these questions in an open forum CC for our benefit? He might be willing to do it but understandably is fed up with the situation and no longer is a stockholder. Nonetheless, no one understands this company, the market and the current management the way he does. Dew put a phenomenal amount of work into the Read me First sections and kept us up to date on most of the latest relevant data and presented some terrific insights into the potential for the products and technology. He moderated some great discussions. My suggestion? Ask him. He has my vote, and I bet the votes of lots of lurkers. We deserve to know our prognosis directly from management in honest and straightforward terms. No doublespeak. Regards, bp
